Jose Manuel Vinuesa-Hernando*, Galadriel Pellejero-Sagastizabal, Mercedes Gimeno-Gracia, Isabel Sanjoaquin-Conde, Maria Jose Crusells-Canales, Raquel Fresquet-Molina and Raquel Gracia-Piquer
Volume3-Issue12
Dates: Received: 2021-12-14 | Accepted: 2022-01-10 | Published: 2022-01-11
Pages: 018-019
Abstract
Objectives: The introduction of dual-therapy both as preferred starting therapy and in switches has been a revolution, allowing the same efficacy results to be obtained as therapies with more Active Ingredients (AI) with a lower risk of toxicity and interactions. The aim of the study is to analyze the efficacy, tolerability and reasons for switching patients to dolutegravir-based dual therapies.
FullText HTML
FullText PDF
DOI: 10.37871/jbres1395
Certificate of Publication
Copyright
© 2022 Vinuesa-Hernando JM, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Vinuesa-Hernando JM, Pellejero-Sagastizábal G, Gimeno-Gracia M, Sanjoaquin-Conde I, Crusells-Canales MJ, Fresquet-Molina R, Gracia-Piquer R. Efficacy and Tolerability of Dolutegravir-Based Dual-Therapies in HIV Naive and Switch Patients. J Biomed Res Environ Sci. 2022 Jan 11; 3(1): 018-019. doi: 10.37871/jbres1395, Article ID: JBRES1395, Available at: https://www.jelsciences.com/articles/jbres1395.pdf